J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences
18 hours ago
Johnson & Johnson agreed to acquire Texas-based biotech Ollin Biosciences for $2.2 billion upfront to expand its eye disease therapy pipeline. The deal includes potential milestone payments up to $1.13 billion and is expected to close before the end of 2026.